4D Molecular Therapeutics, Inc. (FDMT)
| Market Cap | 949.45M |
| Revenue (ttm) | 23.02M |
| Net Income (ttm) | n/a |
| Shares Out | 26.99M |
| EPS (ttm) | -3.05 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 102,975 |
| Open | 35.47 |
| Previous Close | 36.04 |
| Day's Range | 34.70 - 36.04 |
| 52-Week Range | 21.40 - 55.11 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | 50.00 (+42.1%) |
| Est. Earnings Date | Nov 11, 2021 |
About FDMT
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1 clinical trial for the treatment of choroideremia; and 4D-310, which is ...
Financial Performance
In 2020, FDMT's revenue was $13.61 million, an increase of 94.85% compared to the previous year's $6.99 million. Losses were -$56.69 million, 15.0% more than in 2019.
Financial StatementsNews
4D Molecular Therapeutics Announces Late-Breaking Presentation of 4D-125 Clinical Data at the Upcoming ASRS Annual Me...
EMERYVILLE, Calif., Sept. 24, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therap...
4D Molecular Therapeutics Reports Financial Results for the Second Quarter of 2021 and Provides Operational Highlights
EMERYVILLE, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapi...
New Strong Sell Stocks for July 23rd
FDMT, BOOM, FRPT, GEL and HTBK have been added to the Zacks Rank #5 (Strong Sell) List on July 23, 2021.
4D Molecular Therapeutics Announces Rare Disease Ophthalmology Product Candidate Portfolio Update, Including Initial ...
EMERYVILLE, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapi...
4D Molecular Therapeutics Reports Financial Results for the First Quarter of 2021 and Provides Operational Highlights
EMERYVILLE, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapie...
4D Molecular Therapeutics Presents Non-Human Primate Preclinical Data at ASGCT on the 4D-150 Product Candidate for we...
EMERYVILLE, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapie...
4D Molecular Therapeutics Announces Collaboration on Leading Machine Learning Technology and Expertise from U.C. Berk...
EMERYVILLE, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapie...
4D Molecular Therapeutics to Participate in BofA Securities 2021 Virtual Health Care Conference
EMERYVILLE, Calif., April 30, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therap...
4D Molecular Therapeutics Announces Preclinical Data Presentations at ASGCT and ATS Annual Meetings on Three Wholly-O...
- Abstracts on 4D-150 for wet AMD/DME and 4D-310 for Fabry disease accepted for oral presentations at ASGCT 24 th Annual Meeting
4D Molecular Therapeutics Reports Financial Results for the Year Ended December 31, 2020 and Provides Operational Hig...
- First patient dosed in the 4D-310 Phase 1/2 clinical trial in Fabry disease
4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-310 for the Treatment of Fa...
EMERYVILLE, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: 4DMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therap...
Andreas Halvorsen Jumps Into 2 New Biotech Companies
Andreas Halvorsen (Trades, Portfolio) has revealed two new buys in 4D Molecular Therapeutics Inc. (NASDAQ:FDMT) and AbCellera Biologics Inc. (NASDAQ:ABCL), according to GuruFocus' Real-Time Picks, a Pre...
4D Molecular Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to P...
EMERYVILLE, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (4DMT), a clinical-stage gene therapy company harnessing the power...
4D Molecular Therapeutics Announces Upsized Pricing of Initial Public Offering Nasdaq:FMDT
EMERYVILLE, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (4DMT), a clinical-stage gene therapy company harnessing the power...
Gene therapy developer 4D Molecular Therapeutics increases deal size by 58% ahead of $158 million IPO
4D Molecular Therapeutics, a Phase 1/2 gene therapy biotech developing novel AAVs for ophthalmic diseases, raised the proposed deal size for its upcoming IPO on Thursday. The Emeryville, CA-based compan...
It's in the genes: Gene therapy developer 4D Molecular Therapeutics refiles for a $75 million IPO
4D Molecular Therapeutics, which is developing targeted gene therapies for multiple diseases, filed on Tuesday with the SEC to raise up to $75 million in an initial public offering.
4D Molecular Therapeutics IPO Registration Document (S-1)
4D Molecular Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.